Ugur Eskiocak

Company: Voro Therapeutics

Job title: Chief Executive Officer

Seminars:

Tumor-Activated Multi-Specific Biologics for CD47-Targeting Approaches with Improved Therapeutic Index 2:00 pm

Overcoming challenges and amplifying success in CD47-targeting therapies by harnessing clinical learnings Exploring multi-specific antibody-based formats with enhanced phagocytosis compared to the combination of individual components Developing and characterizing masked multi-specific biologics for tumor-selective activityRead more

day: Conference Day One